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Prostate carcinomaMost active cancer immunotherapies able to induce a long-lasting protection against tumours are based
on the activation of tumour-specific cytotoxic T lymphocytes (CTLs). Cell death by hyperthermia induces
apoptosis followed by secondary necrosis, with the production of factors named ‘‘danger associated
molecular pattern” (DAMP) molecules (DAMPs), that activate dendritic cells (DCs) to perform antigen
uptake, processing and presentation, followed by CTLs cross priming. In many published studies, hyper-
thermia treatment of tumour cells is performed at 42–45 C; these temperatures mainly promote cell sur-
face expression of DAMPs. Treatment at 56 C of tumour cells was shown to induce DAMPs secretion
rather than their cell surface expression, improving DC activation and CTL cross priming in vitro.
Thus we tested the relevance of this finding in vivo on the generation of a tumour-specific memory
immune response, in the TRAMP-C2 mouse prostate carcinoma transplantable model. TRAMP-C2 tumour
cells treated at 56 C were able not only to activate DCs in vitro but also to trigger a tumour-specific CTL-
dependent immune response in vivo. Prophylactic vaccination with 56 C-treated TRAMP-C2 tumour cells
alone provided protection against TRAMP-C2 tumour growth in vivo, whilst in the therapeutic regimen,
control of tumour growth was achieved combining immunization with adjuvant chemotherapy.
 2018 Elsevier Ltd. All rights reserved.1. Introduction
In developed countries, prostate cancer (PCa) is the most com-
mon male malignancy [1–3]. If diagnosed prior to metastases for-
mation it may have a long natural course, with a window of
therapeutic intervention. So far, the cytotoxic chemotherapy drugs
showing survival advantage for PCa are docetaxel and carbazitaxel
[1]. Anticancer chemotherapy, as radiotherapy, is largely mediatedby apoptosis of neoplastic cells. Therapy-induced apoptotic tumour
cell death usually progresses to secondary necrosis, increasing
tumour cells immunogenicity when injected into immune-
competent mice [4–6]. Such enhanced immunogenicity relies on
the expression of danger associated pattern (DAMP) molecules
(DAMPs), like high mobility group box 1 (HMGB1) [7]. HMGB1 acti-
vates inflammation and can act as cytokine itself [8]. Chemothera-
peutics such as docetaxel exert cytokine-like immune-stimulatory
properties, improving tumour-protective immune responses as
well [9].
Hyperthermia treatments such as high-intensity focused ultra-
sound (HIFU), radiofrequency ablation (RFA), irreversible electro-
poration (IRE) and microwave ablation (MWA) have emerged as
new ablative treatments for solid tumours. These techniques raise
local tissue temperatures up to 45–85 C, generating lesions with a
central zone at temperatures higher than 60 C where protein
denaturation occurs, causing coagulative necrosis, surrounded by
a transitional zone of sub-lethal hyperthermia (40–60 C) where
cells undergo apoptosis or recover from injury [10]. Inflammatoryodel of
2 F. De Sanctis et al. / Vaccine xxx (2018) xxx–xxxinfiltrates were found both in the transitional zone and in distant,
untreated tumour metastases, suggesting that ablation induced an
overall immune activation, although often too modest to com-
pletely eradicate established tumours [10]. These temperatures
cause tumour cell death with generation of apoptotic material that
can proceed to secondary necrosis and contains DAMPs activating
DC functions of antigen uptake, processing and cross-priming of
cytotoxic T cells (CTLs) [10,11]. The therapeutic efficacy of hyper-
thermia joined to radiotherapy was investigated also in PCa
patients [12–14].
In a mouse PCa transplantable tumour model, intra-tumour
injection of immature DCs (iDCs) after local hyperthermia treat-
ment of tumour at 42–45 C induced tumour-specific immunity
with statistically significant tumour growth reduction [15].
Tumour cells exposure at 42–45 C increased intracellular DAMP
heat shock protein (HSP) 70; temperature raise to 56 C deter-
mined HSP70 and HMGB1 secretion, that strongly improved DCs
activation by reducing iDCs-maturation time and reverting the
immunosuppressive action of tumour cells on CTL cross priming
[16]. Thus, tumour treatment at 56 C was more active than that
at 42–45 C in inducing tumour cells endocytosis and T cell activa-
tion by iDCs and T cell activation [17].
In the present report, the treatment at 56 C was applied to
study both its ability to increase in vitro the immunogenicity of
several human and mouse tumour cell lines of different origin
and to improve in vivo the vaccination efficacy exploiting the trans-
genic adenocarcinoma of the mouse prostate (TRAMP)-C2 trans-
plantable tumour model [18] either in prophylactic or
therapeutic regimen. Docetaxel-based adjuvant chemotherapy
was combined with immunization. In this tumour model we have
previously demonstrated that interferon-c (IFN-c) is critical for
inducing a tumour protective T-cell-mediated immune response,
by simultaneously increasing MHC-I-mediated antigen presenta-
tion and antagonising tumour-secreted TGF-b effects [19].2. Materials and methods
2.1. Cell lines
TRAMP-C1 (ATCC-CRL-2730) and TRAMP-C2 (ATCC-CRL-2731),
a gift of N. Greenberg (Fred Hutchinson Cancer Research Center,
Seattle, WA, USA) [18] and T1525 cell line [20] were cultured
and treated with mouse IFN-c as described [19]. TS/A [21], N202-
1.A [22] LM5 (NT-2) [23] are mouse mammary adenocarcinoma
cell lines; CT26 (ATCC-CRL--2638), C26 and C51 [24] are mouse
colon carcinoma cell lines, all cultured in DMEM with 10% FBS.
Human cell lines, all cultured in RPMI supplemented with 10%
FBS are: MCF-7 (ATCC-HTB-22), MDA-MB-468 (ATCC-HTB-132)
and MDA-MB-231 (ATCC-HTB-26) from mammary adenocarci-
noma; HCT-15 (ATCC-CCL-225), LoVo (ATCC-CCL-229) and HT-29
(ATCC-HTB-38) from colon carcinoma; LNCAP clone FGC (ATCC-
CRL1740), DU145 (ATCC-HTB-81) and PC3 (ATCC-CRL-1435) from
prostatic carcinoma. All cell cultures were incubated at 37 C in
5% CO2 atmosphere.2.2. Generation of DCs
Immature DCs (iDCs) were obtained from the bone marrow
(BM) of C57BL/6J mice according to standard protocols [25] by a
6-day incubation of BM-derived cells in 6-well tissue culture plates
(GREINER Labortechnik, Germany) in complete medium supple-
mented with murine GM-CSF (final concentration: 20 ng/ml) and
murine IL-4 (final concentration: 100 ng/ml) (PEPROTECH, Rocky
Hill, NJ, USA). On day 7th, non-adherent and loosely adherent cells
were collected and used as iDCs.Please cite this article in press as: De Sanctis F et al. Hyperthermic treatment
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Human and murine tumour cell lines in the logarithmic growth
phase, resuspended in fresh culture medium at the concentration
of 25  106/ml, were heated at 56 C for 30 min and then incubated
at 37 C for 4 h [16]. One aliquot of the cell suspension was assayed
for cell death by Annexin V-FITC/PI-PE kit (ROCHE Diagnostics Cor-
poration, Indianapolis, IN, USA), and analysed by flow cytometry.
More precisely, the percentages of early apoptotic (AnnV+/PI), pri-
mary necrotic (AnnV/PI+) and late apoptotic (secondary necrotic)
(AnnV+/PI+) cells were assessed.
For endocytosis assay, tumour cells red-stained with PKH26-PE
(SIGMA, St. Louis, MO, USA) according to the manufacturer’s
instructions were treated 30 min at 56 C, 4 h at 37 C, then mixed
with iDCs (2:1 ratio) in murine GM-CSF- and IL-4-containing med-
ium. Following a 24 h incubation at 37 C, cell mix was stained
with anti-CD11c (clone N418, BD Biosciences, Bedford, MA, USA).
DCs endocytosis was assessed by flow cytometry as the percentage
of double-stained cells [16]. iDCs activation was evaluated as
increase of MHC-II and CD80/86 expression by flow cytometry
with anti-mouse MHC II (M5/114.15.2), CD80 (16-10A1) and
CD86 (GL1) antibodies after co-culture with 56 C-treated or
untreated TRAMP-C2 cells or stimulation with the bacterial endo-
toxin lipopolysaccharide (LPS) (2 mg/ml) used as positive control
of iDC activation [26,27]. In order to confirm iDCs activation, the
supernatant of the same co-cultures described above was collected
and interleukin (IL)-12p70, tumour necrosis factor (TNF)-a, inter-
feron (IFN)-a and chemokine (C-X-C motif) ligand (CXCL)-10
cytokines were quantified by a custom multicytokine ELISA (Pro-
cartaPlex, ThermoFisher, Waltham, Massachusetts, USA).
2.4. Confocal laser scanning microscopy
iDCs were immunomagnetically enriched by CD11c microbeads
(Miltenyi Biotec Bergisch Gladbach, Germany) and labelled with
carboxyfluorescein succinimidyl ester - CFSE (Thermo Fisher, Wal-
tham, Massachusetts, USA) according to manufacturer’s instruc-
tions. CFSE labelled iDCs were co-cultured with PKH26-PE
stained TRAMP-C2 as already described for endocytosis assay. After
24 h cells were washed, placed on glass-slides by cytospin and pro-
cessed for confocal microscopy. Images were acquired on a Leica
TCS SP5 AOBS system (Leica Microsystems) with a 63x oil immer-
sion objective, employing a diode laser at 405 nm for Hochest, an
Ar laser at 488 nm for CFSE and a He/Ne laser at 543 for PKH26-
PE. Images were analysed with LEICA LAS X software.
2.5. ELISA assays
Supernatants derived from tumour cells, treated or not at 56 C
for 30 min and then incubated at 37 C for 4 h, were tested by
ELISA to determine the release of HMGB1, according to manufac-
turer’s instructions (IBL INTERNATIONAL GMBH, Hamburg,
Germany).
Spleen cells of tumour bearing mice were in vitro-stimulated by
5 days-co-culture with c-irradiated (6000 cGy) TRAMP-C2 cells
and the levels of IFN-c produced were evaluated by a mouse IFN-
c ELISA according to manufacturer’s instructions (ARCUS BIOLOGI-
CALS, Modena, Italy).
2.6. In vivo experiments
In vivo experiments were performed with two-months-old
C57BL/6J male mice (Charles River Italia, Calco, Lecco, Italy). A dose
of 5  106 TRAMP-C2 cells, injected subcutaneously (s.c.) in a vol-
ume of 0.2 ml demonstrated to be the minimal dose resulting in
TRAMP-C2 growing tumours in 100% of injected syngeneic animalsat 56 C induces tumour-specific immune protection in a mouse model of
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tumorigenic dose in the present study. The same dose of 56 C-
treated TRAMP-C2 cells was used as vaccine. For this purpose, cells
were re-suspended in fresh culture medium at the concentration of
25  106/ml before 56 C-treatment, to obtain 0.2 ml/cell suspen-
sion aliquots containing 5x106 cell each, ready for s.c. inoculation,
to avoid further manipulations. When indicated, some groups of
mice were also injected s.c. either with 5  106 56 C-treated
TRAMP-C2 cells washed and re-suspended in fresh medium after
56 C-treatment, or with DCs (1  106/mouse) loaded with 56 C-
treated necrotic TRAMP-C2 cells [28]. In therapeutic protocols,
13 days post s.c. inoculation of alive TRAMP-C2 cells, selected
groups received docetaxel preconditioning (20 mg/kg) by
intraperitoneal (i.p.) administration. All animals bearing tumours
were euthanized when the tumour mass reached a volume of
1500 mm3, or became ulcerated or as soon as signs of pain and fati-
gue were perceived. Volumes of sub-cutaneous growing tumours
were measured with callipers twice a week until 60 days from
challenge, chosen as experimental endpoint because in untreated
mice at this time almost all tumours have reached a volume of
1500 mm3. The following formula was used to calculate tumour
mass: (dL  dW  dH)/2, where dL, dW and dH are the three diame-
ters of the mass (length, width and height) [29]. All in vivo exper-
iments were carried out following the EU Directive 2010/63/EU for
animal experiments and are part of a Research Protocol approved
by the Italian Ministry of Health, Decree n. 16/2012-B.
2.7. Statistics
Survival analysis was carried out using the Kaplan-Meier esti-
mator, a non-parametric statistics developed by Kaplan and Meier
[30], and the log-rank test to compare survival of differently
treated-groups [31]. Differences in tumour incidence were also
assessed using v2 test with Yates correction and were considered
statistically significant for P values  0.05. Statistical calculations
were performed using StataTM IC v.10.0 (StataCorp, Texas, USA) for
Microsoft Windows. Statistic analysis for in vitro experiments
was performed by Wilcoxon-Mann-Whitney U test.Fig. 1. Hyperthermia induces apoptosis followed by secondary necrosis and
HMGB1 secretion in TRAMP-C2 cells in vitro. The percentages of either early
apoptotic (AnnV+/PI), primary necrotic (AnnV/PI+) and late apoptotic (secondary
necrotic) (AnnV+/PI+) cells or HMGB1 secretion were assessed in TRAMP-C2 cells
subjected to 30 min of 56 C hyperthermic treatment, followed by 4 h resting at 37
C. (A) Annexin V/PI staining identified apoptosis induction in heat-treated cells
(TRAMP-C2 56 C-treated) compared to untreated control (TRAMP-C2 untreated).
Dot plots refer to a representative experiment out of three. Histograms, mean ± SD
of three independent experiments. Statistic analysis was performed by Wilcoxon-
Mann-Whitney U between TRAMP-C2 cells untreated vs. 56 C-treated TRAMP-C2
cells: AnnV/PI, p = 0.002; AnnV/PI+, p = 0.001; AnnV+/PI+, p = 0.003; AnnV+/PI,
not statistically significant (n.s). (B) ELISA assay of HMGB-1 protein in the
supernatants of untreated or 56 C-treated TRAMP-C2 cells. Data refer to the
mean ± SD of 3 independent experiments. Statistic analysis was performed by
Wilcoxon-Mann-Whitney U test: TRAMP-C2 cells untreated vs. 56 C-treated
TRAMP-C2 cells, p = 0.003.3. Results
3.1. Hyperthermia at 56 C induces apoptosis followed by secondary
necrosis in TRAMP-C2 cells in vitro
Hyperthermia treatment at 56 C of TRAMP-C2 cells increased
significantly the percentages of late apoptotic cells (Fig. 1A) and
HMGB1 release (Fig. 1B) compared untreated TRAMP-C2 control
cells. More precisely, the treatment induced secondary necrosis
in about 90% of cell population; heating time or 37 C incubation
time extensions did not result in any further cell death increase
(data not shown).
3.2. Hyperthermia treatment at 56 C of TRAMP-C2 cells increases iDCs
endocytosis and activation status through tumour cell-derived DAMPs
release
TRAMP-C2 heated cells were then tested for their capability to
be endocytosed by iDCs. iDCs were co-cultured for 24 h with
PKH26-labelled hyperthermia-treated TRAMP-C2 cells and then
stained with anti-CD11c. iDCs endocytosis was evaluated as
double-positive (CD11c+PKH26+) cells by flow cytometry, whereas
PKH26+ CD11c and PKH26CD11c+ cell populations refer to
TRAMP-C2 tumour cells and iDCs respectively. Hyperthermia treat-Please cite this article in press as: De Sanctis F et al. Hyperthermic treatment
prostate cancer in both prophylactic and therapeutic immunization regimens.ment resulted in a statistically significant increase (about 10%) of
endocytosis-engulfed TRAMP-C2 cells by iDCs compared to
untreated cells (Fig. 2A); the strong CD11bPKH26+ cell population
represents TRAMP-C2 cells not engulfed by iDC. These data were
confirmed by confocal laser scanning microscopy (Fig. 2B). The
induction of higher endocytosis activity was coupled withat 56 C induces tumour-specific immune protection in a mouse model of
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Fig. 2. Validation of iDCs maturation after 56 C- treated TRAMP-C2 cells endocytosis. (A) Endocytosis index of untreated or 56 C-treated TRAMP-C2 cells (identified as
PKH26+ cells) by DCs (identified as CD11c+ cells). Dot plots refer to a representative experiment out of three. Double positive CD11c+PKH26+ cells were gated on singlet cells.
Histograms refer to the mean ± SD of 3 independent experiments. Statistic analysis was performed byWilcoxon-Mann-Whitney U test between DCs co-cultured with TRAMP-
C2 cells untreated vs 56 C-treated TRAMP-C2 cells, p = 0.003. (B) Immunofluorescence analysis by confocal microscopy of purified DCs by immunomagnetic sorting as
CD11c+ cells and labelled with FITC-CFSE probe in presence of untreated or 56 C-treated TRAMP-C2 cells labelled with PE-PKH26 probe. Flow cytometry analysis of MHC-II I-
A (C), CD80 (D) and CD86 (E) expression levels on DCs (gated as CD11c+ cells) in presence of different in vitro stimuli: untreated TRAMP-C2 cells (dark grey area and bar); 56
C-treated TRAMP-C2 cells (middle grey area and bar); LPS treatment as positive control (light grey area and bar). Untreated DCs were used as control (black area). Flow
cytometry plots refer to one representative experiment out of five with similar outcome. Histogram plots refer to the mean ± SD of 3 independent experiments. Statistic
analysis by Wilcoxon-Mann-Whitney U test between DCs in presence of untreated TRAMP-C2 cells or 56 C-treated TRAMP-C2 cells: MHC-II I-A (C), p = 0.05; CD80 (D), p =
0.01 and CD86 (E), p = 0.044. (F) TRAMP-C2 cells were treated or not at 56 C for 30 min, followed by incubation at 37 C for 4 h. After that TRAMP-C2 cells were co-incubated
with DCs for 24 h. LPS was used as positive control of DCs activation. The cytokines (IL-12p70, TNF-a, IFN-a and CXCL-10) released in the supernatant of these co-cultures
were quantified by ELISA. Histogram data refer to the mean ± SD of 3 independent experiments. Statistical analysis was performed by Student’s t-test.
4 F. De Sanctis et al. / Vaccine xxx (2018) xxx–xxximproved iDCs maturation, as monitored by a statistically signifi-
cant increase of MHC-II (I-A), CD80 and CD86 activation markers
expression (Fig. 2C–E) and of IL-12p70, TNF-a, IFN-a and CXCL-
10 cytokines production (Fig. 2F), linked to iDC activation [32,33].Please cite this article in press as: De Sanctis F et al. Hyperthermic treatment
prostate cancer in both prophylactic and therapeutic immunization regimens.Thus 56 C-treated TRAMP-C2 cells improve the endocytic
activity of iDCs favouring their maturation to functional mature
DCs (mDCs), by secreting more DAMPs than untreated, similarly
to the treatment with the pathogen associated molecular patternat 56 C induces tumour-specific immune protection in a mouse model of
Vaccine (2018), https://doi.org/10.1016/j.vaccine.2018.05.010
F. De Sanctis et al. / Vaccine xxx (2018) xxx–xxx 5(PAMP) LPS, one of the best known DC activators [26,27], used as a
control of DC activation and maturation.
3.3. In a prophylactic immunization set up, administration of 56 C-
treated TRAMP-C2 cells to naïve mice induces protection against
tumour growth of TRAMP-C2 subsequently inoculated
To test the in vivo vaccination efficacy of 56 C-heated TRAMP-
C2 cells, four groups of C57BL/6J naïve male mice each were immu-
nized according to the following prophylactic schedules (pro-1/4):
pro-1. : s.c. injection of mDCs in vitro-loaded with 56 C trea-
ted TRAMP-C2 cells;
pro-2. : s.c. injection of 56 C treated TRAMP-C2 cells without
washing out supernatant;
pro-3. : s.c. injection of 56 C treated TRAMP-C2 cells washed
out of supernatant and resuspended in PBS;
pro-4. : unvaccinated controls.
Three weeks after immunization, each group of mice was chal-
lenged by s.c. injection with TRAMP-C2, either IFN-c-treated or
untreated.
Tumour growth was monitored twice a week until 60 days from
challenge, which was chosen as experimental endpoint. StatisticalFig. 3. Effects of prophylactic vaccination with 56 C-treated TRAMP-C2 cells on IFN
unvaccinated (pro-4, n = 20; black circle) or immunized with: DCs loaded with 56 C-trea
56 C supernatant (pro-2, n = 20; black triangle) or TRAMP-C2 56 C without supernatan
challenged with IFN-c-treated (n = 10) or untreated TRAMP-C2 cells (n = 10). (A) Overa
analysis by Kaplan Meier log rank test: pro-1 vs. pro-4; p = 0.005. (B) Event free survival
Kaplan Meier log rank test: pro-1 vs pro-4 and pro-3; p < 0.001. (C) OS of mice challenge
Meier log rank test: pro-1 vs pro-4, p < 0.001; pro-1 vs pro-3, p = 0.005. (D) EFS of mice c
Kaplan Meier log rank test: pro-1 vs pro-4 and pro-3, p < 0.001; pro-2 vs pro-4 and pro-3,
irradiated untreated (E) or IFN-c-treated (F) TRAMP-C2 cells in presence of splenocytes
(white bar), pro-2 (light grey bar) or pro-3 (dark grey bar). Statistic analysis was performe
0.022 for panel E; pro-1 vs pro-4, p = 0.04 and pro-2 vs pro-4, p = 0.03 for panel F.
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always performed along the whole time of 60 days from challenge.
We observed an increase in the number of mice that did not
develop tumours (event-free survival = EFS) and in the number of
either tumour-free mice or tumour-bearing mice showing a delay
in tumour growth (overall survival = OS), in almost all mice immu-
nized with pro-1 or pro-2 compared to mice treated with pro-4 or
pro-3.
Among mice challenged with IFN-c-untreated TRAMP-C2 cells
(Fig. 3A and B) we detected a statistically significant increase of
OS only comparing mice immunized with pro-1 to pro-4 (Fig. 3A)
and of EFS comparing mice immunized with pro-1 to pro-4 and
pro-3 (Fig. 3B).
Mice challenged with IFN-c-TRAMP-C2 cells showed a statisti-
cally significant increase of: both OS (Fig. 3C) and EFS (Fig. 3D)
comparing mice immunized with pro-1 to mice immunized with
pro-3 or to pro-4; EFS only when comparing mice immunized with
pro-2 to pro-1 and to pro-3 (Fig. 3D). Thus, the prophylactic vacci-
nation outcome was better appreciated when challenging with
IFN-c-treated TRAMP-C2 cells.
Among the different prophylactic vaccination schedules, pro-1
resulted the most efficient; pro-2 supported tumour protection as
well, but at lower levels. We can speculate that 56 C-treated-c-treated or -untreated TRAMP-C2 tumour growth. C57BL/6J mice were either
ted TRAMP-C2 cells (pro-1, n = 20; white circle), 56 C-treated TRAMP-C2 cells with
t (pro-3, n = 20; white triangle). After three weeks from immunization, mice were
ll survival (OS) of mice challenged by s.c. injection with TRAMP-C2 cells. Statistic
(EFS) of mice challenged by s.c. injection with TRAMP-C2 cells. Statistic analysis by
d by s.c. injection with IFN-c-treated TRAMP-C2 cells. Statistic analysis by Kaplan
hallenged by s.c. injection with IFN-c-treated TRAMP-C2 cells. Statistic analysis by
p = 0.043. (E, F) IFN-c ELISA of supernatants derived from a five-day co-culture of c-
derived from unvaccinated mice (pro-4, black bar), or mice immunized with pro-1
d byWilcoxon-Mann-Whitney U test: pro-1 vs pro-4, p = 0.03 and pro-2 vs. pro-4, p =
at 56 C induces tumour-specific immune protection in a mouse model of
Vaccine (2018), https://doi.org/10.1016/j.vaccine.2018.05.010
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in vivo did not activate resident DCs with the same therapeutic effi-
ciency that is achieved in vitro. If 56 C-treated TRAMP-C2 cells
were washed out of the supernatant before injection (pro-3),
tumour protection was lost, confirming the critical role in DCs acti-
vation played by tumour-derived DAMP release following hyper-
thermia treatment [16].
To confirm the triggering of a TRAMP-C2-specific T cell
response, the supernatants of co-cultures of spleen cells derived
from vaccinated (pro-1/3) and unvaccinated mice with either
TRAMP-C2 cells (Fig. 3E) or TRAMP-C2 cells pre-treated with IFN-
c (Fig. 3F), were tested by IFN-c ELISA. Tumour-spleen cells co-
cultures from mice immunized with either pro-1 or pro-2 com-
pared to cultures of spleen cells from both mice immunized with
pro-3 or pro-4, showed a statistically significant increase of IFN-c
production (Fig. 3E and F). Immunization with pro-1 and pro-2
induced a similar specific T cell response against tumour, suggest-
ing that in pro-2, 56 C-treated TRAMP-C2 cells are endocytosed byFig. 4. Efficacy of therapeutic vaccination with mDCs loaded with 56 C-treated TRAMP-
were injected s.c. with 5  106 TRAMP-C2 cells. Thirteen days later, tumour-bearing mice
and vaccination with 56 C-treated-TRAMP-C2 in vitro-loaded mDCs (n = 13, white tria
mDCs (n = 13, white circle); ther-3, docetaxel treatment (n = 13, black triangle) and ther-4
reported as tumour volume variations over the time. Statistic analysis was performed usi
and ther-1 vs ther-3, p = 0.017. (B) Overall survival (%) of treated mice. Statistic analysis by
(C) and (D) IFN-c ELISA of supernatants derived from a five-day co-culture of c-irradia
isolated from treated mice. Statistic analysis was performed by Wilcoxon-Mann-Whitney
2 vs ther-4, p  0.0001 and ther-2 vs ther-1, p  0.0001 for panel E.
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pro-3, highlighting the functional role of tumour-derived DAMPs in
triggering a tumour-specific cytotoxic immune response.
3.4. In a therapeutic immunization set up, administration of mDCs
loaded with 56 C-treated TRAMP-C2 cells to tumour-bearing mice
induces protection against TRAMP-C2 tumour growth only when
combined with chemotherapy
Given the promising results achieved immunizing with mDCs
in vitro-loaded with 56 C-treated TRAMP-C2 in the prophylactic
set up (Fig. 3), we explored the feasibility of this approach in a
therapeutic regimen, either alone or in association with docetaxel
chemotherapy [1] (Fig. 4).
Naïve mice were injected s.c. with 5  106 tumorigenic TRAMP-
C2 cells. Thirteen days later, they were divided in four groups
according to therapeutic immunization schedule (ther-1/4) as
follows:C2- associated to chemotherapy on TRAMP-C2 tumour growth. Naïve mice (n = 54)
were treated according to the following schedules: ther-1, combination of docetaxel
ngle); ther-2, vaccination treatment with 56 C-treated-TRAMP-C2 in vitro-loaded
, untreated control mice (n = 15, black circle). A) Tumour growth of treated mice was
ng v2 test with Yates correction: ther-1 vs ther-4, p = 0.002; ther-1 vs ther-2, p = 0.03
Kaplan Meier log rank test: ther-1 vs ther-4, p = 0.007 and ther-1 vs ther-3, p = 0.002.
ted untreated (C) or IFN-c-treated (D) TRAMP-C2 cells in presence of splenocytes
U test: ther-2 vs ther-4, p  0.0001 and ther-2 vs ther-1, p  0.0001 for panel C; ther-
at 56 C induces tumour-specific immune protection in a mouse model of
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F. De Sanctis et al. / Vaccine xxx (2018) xxx–xxx 7ther-1. : combination of docetaxel preconditioning, followed
two days later by vaccination with mDCs in vitro-
loaded with 56 C-treated-TRAMP-C2 delivered s.c.;
ther-2. : vaccination treatment only, with mDCs in vitro-loaded
with 56 C-treated-TRAMP-C2 delivered s.c.;
ther-3. : docetaxel treatment only;
ther-4. : control mice unvaccinated and docetaxel-untreated.
Only the combination of docetaxel and vaccination treatments
induced a statistically significant reduction of tumour growth ratesFig. 5. Quantification of apoptosis/secondary necrosis and HMGB1 release in different hu
and murine tumour cell lines of different histologic types were treated at 56 C and th
supernatant were compared. Histograms colour: dark grey for human mammary adeno
human colon carcinoma; light grey dashed for mouse colon carcinoma; white for human p
mean ± SD of 3 independent experiments. (A) Fold increase (D) of late apoptotic cells (A
increase (D) of HMGB1 release by late apoptotic cells after 56 C hyperthermic treatme
Please cite this article in press as: De Sanctis F et al. Hyperthermic treatment
prostate cancer in both prophylactic and therapeutic immunization regimens.(Fig. 4A) and increased overall survival, compared to the other
treatments (Fig. 4B).
To test the presence of a TRAMP-C2-specific T cell response,
spleen cells derived from 5 mice from each treatment group were
co-cultured with IFN-c-untreated and IFN-c-treated TRAMP-C2
cell targets, and supernatants were analysed for the presence of
IFN-c as activation index of spleen-derived T cells, in ELISA assays
(Fig. 4C and D). A statistically significant increase of IFN-c produc-
tion was found comparing ther-4 to ther-2, ther-4 to ther-1 and
ther-2 to ther-1, against both IFN-c-conditioned and IFN-c-
unconditioned TRAMP-C2 targets.man and murine tumour cell lines following 56 C hyperthermia treatment. Human
e levels of late apoptosis/secondary necrosis induction and HMGB1 release in the
carcinoma; dark grey dashed for mouse mammary adenocarcinoma; light grey for
rostate cancer; white dashed for mouse prostate cancer. Histogram data refer to the
nnexinV+/PI+) after 56 C hyperthermic treatment, compared to untreated. (B) Fold
nt, compared to untreated.
at 56 C induces tumour-specific immune protection in a mouse model of
Vaccine (2018), https://doi.org/10.1016/j.vaccine.2018.05.010
8 F. De Sanctis et al. / Vaccine xxx (2018) xxx–xxxThus, the vaccination regimen alone or in association with
chemotherapy promoted a TRAMP-C2-specific immune response,
which in the absence of chemotherapy was not able to contrast
tumour growth efficiently. Finally, the docetaxel treatment alone
did not elicit any TRAMP-C2-specific immune response, as the
IFN-c secretion levels were comparable to those of untreated
animals.3.5. Hyperthermia at 56 C induces apoptosis followed by secondary
necrosis in human and mouse cancer cell lines derived from different
tissues in vitro
The 56 C hyperthermia protocol used to treat TRAMP-C2 cells
in vitro was applied to evaluate the induction of late apoptosis
and of HMGB1 release in several human and mouse tumour cell
lines of different histologic origin (Fig. 5). In general, the percent-
age of late apoptotic cells increased after thermic treatment
(Fig. 5A). Conversely, the levels of secreted HMGB1 in the super-
natant of heat-treated cell lines increased with respect to the
untreated control in all the tested tumour cell lines, at different
levels (Fig. 5B). Therefore, hyperthermia at 56 C as immunothera-
peutic approach, appears to be eligible to treat a large spectrum of
tumours with different histology.4. Discussion
Our data demonstrate that triggering a tumour-protective
immune response using an immunotherapeutic strategy based on
56 C-hyperthermia-treated TRAMP-C2 tumour cell vaccine is fea-
sible. This approach appears more translatable to clinical protocols
than genetically modified tumour cells, recently explored in the
same model [19].
56 C-treated TRAMP-C2 vaccine induced an in vivo protection,
provided that the DAMPs-containing-56 C-incubating super-
natant was present in the immunizing inoculum, although with a
lower impact than immunization with mDCs in vitro-loaded with
56 C-treated TRAMP-C2 cells. A reasonable explanation is that
not all the material can be sensed and up-taken by resident DCs
in vivo as it may happen in vitro. According to that, immunization
with 56 C-treated tumour cells washed after heating did not pro-
tect against tumour growth, because host DCs were not activated
in the absence of DAMPs.
IFN-c treatment prior tumour challenge rendered tumour cells
more susceptible to CTL killing, through the up-regulation of anti-
gen processing machinery (APM) TAP-1/TAP-2 and LMP-2/LMP-7
components, associated with an increase of cell-surface expression
of MHC-I/peptide complexes [19]. Accordingly, down-regulation of
MHC-I expression is a frequent feature of PCa [34,35], sometimes
controversial [36]. As some human prostate carcinoma cell lines,
TRAMP-C2 shows a down-regulated MHC-I expression [37,38],
due to the inhibitory effect of tumour-secreted TGF-b, counter-
regulated by the IFN-c-treatment [19].
To evaluate the translatability of this vaccination approach to
clinics, we switched to a therapeutic vaccination set up. DCs loaded
with 56 C-treated TRAMP-C2 vaccine was tested alone or associ-
ated to docetaxel chemotherapy. The overall survival dropped
down compared to prophylactic immunization, although the
results obtained with the combined treatment docetaxel/immu-
nization showed a statistically significant reduction of both
tumour growth rate and increase of overall survival, compared to
single treatments.
In the TRAMP-C2 system, this 56 C hyperthermia protocol
appeared to work better than high hydrostatic pressure, that raised
a specific CD8+ T cell response without decreasing tumour growth
rates, and when combined with docetaxel produced similar results,Please cite this article in press as: De Sanctis F et al. Hyperthermic treatment
prostate cancer in both prophylactic and therapeutic immunization regimens.although with three deliveries administered at alternate weeks,
whilst our results were obtained with one single delivery of 56
C-treated-TRAMP-C2 combined with docetaxel [39].
In addition to its cytotoxic effects on PCa [1], docetaxel induces
immunogenic modulation by increasing TAP-2 and calnexin APM
molecules expression [40]. Thus, in the TRAMP-C2 tumour model,
similarly to what we previously described for IFN-c [19], docetaxel
creates synergy with the 56 C-treated-TRAMP-C2 therapeutic
immunization regimen, resulting in a tumour-protective effect
able to delay tumour growth in a statistically significant manner.
These results have potential clinical implications, strengthening
the importance of combination protocols of immunotherapy and
chemotherapy, and in the context of PCa, the synergic role of
hyperthermia and docetaxel in the enhancement of specific anti-
tumour immune response.5. Conclusions
The results presented here strongly favour the translatability of
the 56 C hyperthermia treatment to clinics in association to doc-
etaxel, by modulating the thermal energy applied and the time of
application in HIFU, RFA, IRE or MWA treatments, in order to
extend the transitional zone of sub-lethal hyperthermia at temper-
atures close to 56 C, to increase the release of DAMP molecules
and pro-inflammatory cytokines from tumour cells.
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